Autolus Therapeutics plc
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Autolus Therapeutics (AUTL) reported Q2 2026 revenue of $45.7M, up 119% YoY, driven by AUCATZYL sales. The company raised full-year guidance to $140M-$150M and secured a $250M credit facility. Despite improved margins, Autolus posted a $39.1M net loss and cash decreased to $201.6M. AUCATZYL carries significant safety warnings, and $150M of financing is tied to revenue milestones.
Autolus Therapeutics (AUTL) announced FDA's RMAT designation for obe-cel, its lead CAR T cell therapy, for treating lupus and lupus nephritis. The designation accelerates development in the ongoing Phase 2 LUMINA trial. AUTL stock closed at $2.11, down 5.80%, and is up 1.50% in pre-market trading.
Autolus (AUTL) reported Q2 2026 net product revenue of $45.7M, up 119% YoY, and raised full-year guidance to $140M-$150M. Gross margin improved to 55%, and cash runway extends into Q2 2028. The company expanded treatment centers and saw initial U.K. sales.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning AUTL (Autolus Therapeutics plc). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent AUTL coverage spans earnings, regulation and financial news.
In the last 30 days, AUTL insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($16K). The most active reporter was Piccina Cintia, U.S. CCO & Country Gen Manager, with 1 filing.
Strong revenue growth and raised guidance may support upside, but widening SG&A and ongoing net loss limit upside.
Regulatory designation may accelerate trial timelines and boost valuation.
Guidance and margin trajectory improve near-term revenue confidence, while cash runway and financing reduce dilution risk concerns.
This is a new, disclosed large stake that can shift near-term positioning and sentiment, but it does not by itself change fundamentals or guidance.
Street expectations improved on revenue and narrowing losses, but the unchanged consensus price target suggests limited valuation repricing near term.
AlphAI scores every news story that mentions AUTL with an AI model for sentiment and relevance, and aggregates insider trades from Autolus Therapeutics plc's SEC EDGAR Form 4 filings. Figures refresh continuously.
Autolus Therapeutics (AUTL) reported Q2 2026 revenue of $45.7M, up 119% YoY, driven by AUCATZYL sales. The company raised full-year guidance to $140M-$150M and secured a $250M credit facility. Despite improved margins, Autolus posted a $39.1M net loss and cash decreased to $201.6M. AUCATZYL carries significant safety warnings, and $150M of financing is tied to revenue milestones.
3 min readAutolus Therapeutics (AUTL) announced FDA's RMAT designation for obe-cel, its lead CAR T cell therapy, for treating lupus and lupus nephritis. The designation accelerates development in the ongoing Phase 2 LUMINA trial. AUTL stock closed at $2.11, down 5.80%, and is up 1.50% in pre-market trading.
2 min readAutolus (AUTL) reported Q2 2026 net product revenue of $45.7M, up 119% YoY, and raised full-year guidance to $140M-$150M. Gross margin improved to 55%, and cash runway extends into Q2 2028. The company expanded treatment centers and saw initial U.K. sales.
6 min readArmistice Capital, LLC and Steven Boyd disclosed beneficial ownership of 15,000,000 Autolus Therapeutics plc ADSs, representing 5.64% of the ADSs outstanding, in a filing. They report shared voting and dispositive power over the stake via Armistice Capital Master Fund Ltd., with dividends and sale proceeds rights remaining with the Master Fund.
2 min readAutolus Therapeutics plc (NASDAQ:AUTL) reported quarterly results with revenue of $46m, above expectations, and a statutory loss of $0.15 per share. Analysts upgraded 2026 forecasts to $149.8m revenue (+28%) and $0.77 loss per share (from $139.4m and $0.84). The consensus price target stayed at $8.73.
3 min readAutolus Therapeutics (NASDAQ:AUTL) shares rose in pre-market after Q2 results beat expectations and the company raised full-year AUCATZYL net product revenue guidance to $140 million to $150 million. Q2 loss was $0.15 per share versus $0.23 expected, with revenue of $45.7 million. Gross margin improved to 55% from 6% in Q1.
5 min readAutolus Therapeutics (AUTL) reported Q2 2026 AUCATZYL net product revenue of $45.7M, up from $20.9M in Q2 2025 and $26.2M in Q1 2026, with improving gross margins. The company raised FY26 AUCATZYL guidance to $140M-$150M from $120M-$135M (FY25: $74.3M). It also secured a $250M credit facility with Perceptive Advisors and expects cash to fund operations into Q2 2028.
4 min readAutolus Therapeutics plc (AUTL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Autolus Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates August 11, 2026 at 7:00 AM EDT Company reports AUCATZYL® (obecabtagene autoleucel; obe-cel) net product revenue of $45.7 million in Q2 2026, an increase of 119% year-over-year FY 2026 net prod
3 min readAutolus Therapeutics plc (Nasdaq: AUTL) reported Q2 2026 net product revenue of $45.7 million for AUCATZYL (obe-cel), up 119% year over year. FY 2026 guidance was raised to $140-$150 million. Gross margin improved to 55%. The company secured up to $250 million in five-year interest-only credit facility financing with Perceptive Advisors and updated clinical trial enrollment across obe-cel programs.
6 min readAutolus Therapeutics plc (Nasdaq: AUTL) said it secured a senior secured notes facility up to $250 million with Perceptive Advisors, including $75 million upfront, $25 million at Autolus’ option, and up to $150 million tied to revenue milestones. Autolus issued warrants for up to 3.5 million ADS. The company expects funding into Q2 2028.
2 min read
